Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...

A partial autopsy also found that the former One Direction singer had a recreational substance known as “pink cocaine” in his ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

A couple from Hull have called on the government to fund new Alzheimer's drugs, even though they say it will come "too late" ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

The drug, and another new drug for Alzheimer's called lecanemab, have been billed as a huge step forward in research because ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news ...

Patient Peter Almond told of his disappointment that donanemab will only be available to those who can pay for a private ...

This is the second time a new Alzheimer's treatment has been rejected by the health spending watchdog in a matter of months.

NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate ...